Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Parabilis Medicines, Inc. (PBLS) had Stock-Based Compensation of $3.32M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-186.93M |
|
-- |
|
-- |
|
$152.08M |
|
$-152.08M |
|
$6.19M |
|
$-145.89M |
|
$-145.89M |
|
$-145.89M |
|
$-145.89M |
|
$-145.89M |
|
$-145.89M |
|
$-152.08M |
|
$-148.97M |
|
2.02M |
|
2.02M |
|
$-92.40 |
|
$-92.40 |
|
| Balance Sheet Financials | |
$29.36M |
|
$6.71M |
|
$51.46M |
|
$80.82M |
|
$56.79M |
|
$1.47M |
|
$40.55M |
|
$97.34M |
|
$-526.50M |
|
$-16.52M |
|
$-16.52M |
|
2.04M |
|
| Cash Flow Statement Financials | |
$-123.71M |
|
$39.76M |
|
$64.38M |
|
$50.14M |
|
$30.57M |
|
$-19.57M |
|
|
Stock-Based Compensation |
$3.32M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.52 |
|
-- |
|
-- |
|
-0.10 |
|
-0.92 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-124.02M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
27.71% |
|
882.89% |
|
-180.51% |
|
969.10% |
|
$-8.12 |
|
$-61.30 |
|
$-61.15 |
|